List view / Grid view
The dose finding study will assess the safety, reactogenicity and…
The dose finding study will assess the safety, reactogenicity and immunogenicity of the companies’ investigational COVID-19 vaccine in 720 participants.
MenQuadfi® has been approved for use in individuals 12 months…
MenQuadfi® has been approved for use in individuals 12 months of age and older, based on its safety and immunogenicity in 6,300 trial subjects.
Sanofi and GSK have agreed to support the COVID-19 vaccine…
Sanofi and GSK have agreed to support the COVID-19 vaccine (COVAX) Facility with 200 million doses of their adjuvanted, recombinant protein-based COVID-19 vaccine.
Sanofi and GSK have reached an agreement with the UK…
Sanofi and GSK have reached an agreement with the UK government to supply up to 60 million doses of their COVID-19 vaccine.
